OTLK (Outlook Therapeutics) Buyback Yield %: -18.77 (As of Jul. 12, 2026)


OTLK Outlook Therapeutics Inc OTLK
19 GF Score
Price $1.58
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics Buyback Yield %?

Outlook Therapeutics OTLK -6.55% 19 Buyback Yield % is -18.77 as of Jul. 12, 2026. GuruFocus rates OTLK with a GF Score™ of 19/100. The stock has 6 warning signs investors should review. Among 742 Biotechnology companies, Outlook Therapeutics ranks worse than 66.44% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Outlook Therapeutics's current buyback yield was -18.77%.

Outlook Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Buyback Yield % Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.09 -22.47 -52.20 -47.26 -44.46

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.31 -24.72 -44.46 -37.83 -204.69

OTLK vs FULC, OBIO, ACIU: Buyback Yield % Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Buyback Yield % falls into.


OTLK
19GF Score
Outlook Therapeutics Inc OTLK
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Outlook Therapeutics's Buyback Yield for the fiscal year that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 25.396) / 57.12022
=-44.46%

Outlook Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 44.069) / 21.5295612
=-204.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -18.77 mean?
Outlook Therapeutics (OTLK) has a Buyback Yield % of -18.77 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #493 out of 742 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Outlook Therapeutics' Buyback Yield % too high?
Outlook Therapeutics' current Buyback Yield % is -18.77. Based on the distribution chart, Outlook Therapeutics ranks #493 out of 742 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Outlook Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Buyback Yield % compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #493 out of 742 companies for Buyback Yield %. This places Outlook Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Buyback Yield % is -18.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Buyback Yield % of -18.77. The current Buyback Yield % is -18.77. Outlook Therapeutics' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Buyback Yield % is -18.77 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
19GF Score

Get the complete analysis for OTLK

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.58
Price